Bioventus, Inc. ( (BVS) ) has released its Q4 earnings. Here is a breakdown of the information Bioventus, Inc. presented to its investors.
Bioventus Inc., a global leader in innovations for active healing, specializes in providing clinically proven, cost-effective products for pain treatments, surgical solutions, and restorative therapies. The company operates in the healthcare sector and is known for its commitment to high-quality standards and evidence-based medicine.
Bioventus recently announced its financial results for the fourth quarter and full year of 2024, highlighting significant growth and strategic advancements. The company reported accelerated sales growth and improved margins, reflecting a successful and transformational year.
In the fourth quarter, Bioventus achieved a 13.5% increase in worldwide revenue, totaling $153.6 million, driven by robust growth in pain treatments and surgical solutions. The adjusted EBITDA rose by 28.3%, and the net loss from continuing operations significantly decreased compared to the previous year. For the full year, revenue increased by 11.9% to $573.3 million, with a notable improvement in adjusted EBITDA and a reduction in net loss from continuing operations. The company also divested its Advanced Rehabilitation Business, enhancing its financial position by reducing long-term debt.
Looking ahead, Bioventus has provided financial guidance for 2025, projecting net sales between $560 million and $570 million, with organic growth anticipated between 6.1% and 8.0%. The company expects adjusted EBITDA to grow, reflecting an increase in adjusted EBITDA margin, and forecasts a rise in non-GAAP earnings per share.
Bioventus remains focused on building on its positive momentum, aiming to drive above-market revenue growth and enhance profitability. The company’s strategic priorities and diverse growth drivers position it well for continued success in the coming year.